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Artemisia argyi isawidelyusedmedicinalplantinChina.Thepresentstudywasdesignedtoidentifythebioactiveconstituentswith
antiglioma activity from leaves of Artemesia argyi. A bioactivity guided approach based on MTT assay for cells growth inhibition
led to the isolation of a ﬂavonoid, “jaceosidin” from ethanol extract of leaves of Artemesia argyi. The growth inhibitory eﬀect of
jaceosidinwasexploredusingﬂowcytometryandWesternblotstudies.Ourresultsshowedthatjaceosidinexertsgrowthinhibitory
eﬀect by arresting the cells at G2/M phase and induction of apoptosis. Furthermore, our study revealed that induction of apoptosis
was associated with cell cycle arrest at G2/M phase, upregulation of p53 and Bax, decrease in mitochondrial membrane potential,
release of cytochrome c, and activation of caspase 3. This mitochondrial-caspase-3-dependent apoptosis pathway was conﬁrmed
by pretreatment with caspase 3 inhibitor, Ac-DEVD-CHO. Our ﬁndings suggested that jaceosidin induces mitochondrial-caspase-
3-dependent apoptosis in U87 cells by arresting the cell cycle at G2/M phase.
1.Introduction
The genus Artemisia, belonging to the Compositae fam-
ily, comprises around 500 species which are widespread
throughouttheworld.Artemisia plantsareimportantmedic-
inal plants and have long been used in Chinese traditional
medicines (TCM) to treat microbial infections, inﬂam-
matory diseases, diarrhea, gastric ulcer, malaria, hepatitis,
cancer, and circulatory disorders [1–3].
Several phytochemical studies conducted on Artemisia
plants have revealed the presence of coumarins, glycosides,
sterols, polyacetylenes, monoterpenes, triterpenes, sesquiter-
pene lactones, ﬂavonoids, polysaccharides, and essential oils
[1, 3, 4]. Among ﬂavonoid constituents, eupatiline, and jac-
eosidin got enormous attention due to their broad spectrum
pharmacological activities including antiulcer, antiallergic,
antidiabetic, antimutagenic, antiproliferative, antiinﬂamma-
tory, antioxidative, and anticancer activities [5].
So far, jaceosidin has been reported to exhibit only a few
chemoprevention-related pharmacological activities such as
inhibition of COX-2 and MMP-9 in human mammary epi-
thelial cells, suppression of E6 and E7 oncoproteins of HPV
16, induction of apoptosis in ras-transformed human breast
epithelial cells and human ovary cancer cells [6–9]. However
no information is at present available on the chemoprevent-
ive potential of jaceosidin on gliomas.
In the present study, we have isolated and puriﬁed
jaceosidin from the leaves of Artemisia argyi by high-per-
formance liquid chromatography (HPLC) and high-speed
countercurrentchromatography(HSCCC).Furthermore,we
investigated that the induction of apoptosis, mediated by
jaceosidin in U87 glioma cells, evidenced by Bax activation,
mitochondrialcytochromecreleaseandcaspase3activation,
was associated with cell cycle arrest at G2/M phase. Inhi-
bition of caspase 3 did not prevent the G2/M phase arrest.2 Evidence-Based Complementary and Alternative Medicine
These ﬁndings suggest that jaceosidin induced apoptosis is
resulted from mitotic arrest.
2.MaterialsandMethods
2.1. Materials. The dried leaves of Artemisia argyi were
purchasedfromYunnanQiancaoyuanMedicinalPlantCom-
pany (Yunnan, China) and identiﬁed by associate Pro-
fessor Diao Yunpeng (Dalian Medical University, Dalian,
China). Jaceosidin was isolated with 99.5% purity from
leaves of Artemisia argyi. All the chemicals for extraction
process were purchased from Honeywell Burdick & Jack-
son (USA). Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)
culture medium, Roswell Park Memorial Institute medium
(RPMI 1640), fatal bovine serum (FBS), Propidium iodide
(PI), RNase A, Rhodamine 123, [3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium Bromide] (MTT), calcein
acetoxymethyl-ester (calcein AM); and dimethyl sulfoxide
(DMSO) were purchased from Sigma (Beijing, China).
Annexin V-FITC Apoptosis Detection Kit, reactive oxygen
species assay kit, and caspase 3 inhibitor, Ac-DEVD-CHO,
were purchased from Beyotime (Shanghai, China). Antibod-
ies speciﬁce to p53, bax, cytochrome c, and caspase 3 were
purchased from Beyotime (Shanghai, China) while β-actin
and secondary antibodies were purchased from Santa Cruz
(USA).
2.2. Extraction and Isolation. Dried leaves of Artemisia argyi
were extracted with 95% ethanol. The ethanol extract was
evaporated to dryness by using a rotor evaporator machine
at 90◦Cu n d e rr e d u c e dp r e s s u r et og e tc r u d ee x t r a c t .T h e
crude extract was then dissolved in 80% methanol and frac-
tionatedinto 80fractionsbyusing 0–90% methanolgradient
on preparative high-performance liquid chromatography
(HPLC) equipped with 2489 UV/visible detector, 2495
separationmoduleand2767collector(WATERS,USA).Each
fraction was dried and dissolved in DMSO (10mg/mL). All
fractions were then screened against U87 glioblastoma cells
at ﬁnal concentration of 100μg/mL to identify bioactive
fraction. After the identiﬁcation of bioactive fraction, the
crudeextractwasthenextractedwithdiﬀerentsolventstoget
maximum solubility of target peak (bioactive fraction) and
further puriﬁed by high-speed countercurrent chromatogra-
phy (HSCCC).
2.3. HSCCC Apparatus. The HSCCC instrument employed
inthepresentstudyisTBE-300HSCCC(TautoBiotechnique
Company, Shanghai, China) with three multilayer coil
separation columns connected in series (ID of the tubing =
1.8mm, total volume = 280mL). The revolution radius was
5cm, and the β values of the multilayer coil varied from 0.6
at the internal terminal to 0.8 at the external terminal. The
speed of revolution of the apparatus could be regulated with
a speed controller within the range 0–1000rpm. The solvent
was infused into the column using a TBP-50A pump (Tauto
Biotechnique Company, Shanghai, China), and the eluent
was continuously monitored by connecting the tail outlet
of the coiled column to TBD-23UV (Tauto Biotechnique
Company, Shanghai, China) system.
2.4. Preparation of the Two-Phase Solvent System and Sample
Solution. The solvent system of n-hexane/ethyl acetate/me-
thanol/water was optimized to the ratio of 1:1:1:3
(v/v/v/v). The two-phase solvent system was prepared by
adding the solvents to a separation funnel according to the
volume ratios and fully equilibrated by shaking repeatedly
at room temperature. The upper and lower phases were
separated shortly before use and degassed by sonication for
30min. 30mg of bioactive fraction were dissolved in 10mL
lower phase.
2.5. HSCCC Separation Procedure. The whole procedure was
carried out as follows: the coil column was ﬁrst ﬁlled with
the upper phase of n-hexane/ethyl acetate/methanol/water
( 1 : 1 : 1 : 3b yv o l u m e )a taﬂ o wr a t eo f1 0 m L / m i n .T h e
apparatus was rotated at 800rpm, while the lower phase was
pumped into the column at a ﬂow rate of 2.0mL/min. After
the mobile phase front emerged and hydrodynamic equilib-
rium was established in the column, 10mL sample solution
was injected through the injector. The eﬄuent from the
outlet of the column was continuously monitored at 254nm
by UV–Vis detector and N2000 Station. Each peak fraction
was manually collected according to the chromatogram
a n de v a p o r a t e du n d e rr e d u c e dp r e s s u r e .T h er e s i d u ew a s
dissolved in acetonitrile for subsequent HPLC analysis.
2.6. HPLC Analysis and Identiﬁcation of HSCCC Peak Frac-
tion. The peak fraction obtained by HSCCC was analyzed
by analytical reversed-phase (RP) HPLC (WATERS 2695).
T h ec o l u m nu s e dw a sX T e r r aM SC 1 8( 5μM, 2.1×150mm).
The mobile phase composed of acetonitrile (A) and 0.2%
formic acid (B) was eluted with linear gradient elution
(A: 0–25min, 10–90%; 25–30min, 90–100%). The injection
volume was 10μLandﬂowratewas0.2mL/min.Theeﬄuent
was monitored at 342nm. Identiﬁcation of the peak was
carried out by liquid chromatography/mass spectrometry
(LC/MS) and nuclear magnetic resonance (NMR). Mass
spectrometry was performed using a Quattro Micro (Waters,
USA) scanning from 50–1000m/z. 1Ha n d13C NMR spectra
were recorded on Bruker Avance 500 spectrometer (Bruker
Optics-Beijing, China) operating at 500MHz for 1Ha n d
100MHz for 13C.
2.7. Cell Culture. U87 cell line was purchased from the
American Type Culture Collection (ATCC, USA) and cul-
t u r e di nD M E Mm e d i u ms u p p l e m e n t e dw i t h1 0 %( v / v )
heat-inactivated FBS. Mouse splenocytes were freshly iso-
lated from C57 mice (Central Research Laboratory, second
Clinical Hospital, Changchun, China) and cultured in RPMI
1640mediumsupplementedwith10%(v/v)heat-inactivated
FBS and maintained at 37◦C with 5% CO2 in humidiﬁed
atmosphere.
2.8. Determination of Cell Viability. The eﬀect of jaceosidin
on cell viability was measured by MTT assay. Brieﬂy, 5000Evidence-Based Complementary and Alternative Medicine 3
cells were seeded into 96 well tissue culture plates. After 24-
hour incubation at 37◦C, cells were treated with diﬀerent
concentrations of jaceosidin (30μM to 300μM) for 24 hours
and 48 hours. The MTT reagent was then added to each well
(500μg/mL), and the cells were further incubated for 4 h.
Subsequently, 150μL DMSO was added to dissolve farmazan
crystals,andabsorbancewasmeasuredat570nminathermo
microplate reader (Thermo Scientiﬁc, USA). Results were
expressedasthepercentageofMTTreduction,assumingthat
the absorbance of control cells was 100%.
2.9. Morphological Changes of U87 Cells by Light Microscopy.
U87 cells were treated with jaceosidin (100μM/L) for 24h
and 48h. Morphological changes were observed by phase
contrast microscopy (Olympus 1 × 71, Japan). Freshly
isolated mouse splenocytes were treated with or without
jaceosidin (100μM/L) for 24h and 48h. After treatment,
cells were stained with 0.4% trypan blue and were counted
microscopically for the percentage of dead and live cells.
2.10. Live/Dead Cells Assay. Live and dead cells were quanti-
ﬁed using the ﬂuorescent probes calcein AM and PI. Calcein
AM is highly lipophilic and cell membrane permeable. In
viable cells, it is converted into calcein by Esterases and
emits strong green ﬂuorescence. PI, a nuclei-staining dye,
cannot pass through a viable cell membrane. Cells with
impaired plasma membrane integrity are stained red due to
entry of PI and failure to retain calcein. Since both calcein
and PI-DNA can be excited with 490nm, simultaneous
monitoring of viable and dead cells is possible with a
ﬂuorescence microscope (Olympus 1 × 71, Japan). U87
cells were incubated with or without 100μM jaceosidin for
24h and 48h. After incubation, ﬂoating and adherent cells
were collected, washed with PBS, and incubated with PBS
solution, containing 2μM calcein AM and 4μM PI in the
dark for 20min at room temperature. At the end, 100 cells
were counted microscopically for the percentage of live and
dead cells.
2.11. Flow Cytometric Analysis of Cell Death. U87 cells were
treated with or without 100μM of jaceosidin, in the presence
or absence of 100μM caspase 3 inhibitor, Ac-DEVD-CHO,
for 24h and 48h. The cells were harvested, rinsed twice
with PBS, and labeled with 5uL FITC-conjugated annexin
V according to the manufacturer’s instructions (Beyotime,
Shanghai, China). After incubation in dark for 10min and
then labeled with PI, the samples were immediately analyzed
on a ﬂow cytometer (Beckman Coulter, Epics XL).
2.12. Flow Cytometric Analysis of Cell Cycle. U87 cells were
treated with or without 100μM of jaceosidin for 24h and
48 h. The cells were then washed with PBS and ﬁxed with
70% ice-cold ethanol at 4◦C for overnight. After washing
twice with PBS, cells were stained with a solution containing
50μg/mL of PI and 100μg/mL RNase A for 30min in the
dark at room temperature. The stained cells were analyzed
by ﬂow cytometry (Beckman Coulter, Epics XL).
2.13. Determination of Reactive Oxygen Species (ROS) Gen-
eration. The changes in the intracellular reactive oxygen
species generation were measured by staining the cells with
2 ,7 -dichlorﬂuorescein-diacetate (DCFH-DA). Brieﬂy, U87
cell were incubated in 6 well culture plates for overnight.
After treating the cells with or without 100μM of jaceosidin
for24hand48h,cellswerefurtherincubatedwith10μmol/L
DCFH-DA at 37◦C for 30min according to manufacturer’s
instruction (Beyotime, Shanghai, China). In the positive
controlgroup,cellslabeledwithDCFH-DAweretreatedwith
1μL rose up for 30min. Subsequently, cells were collected,
rinsed, resuspended in PBS, ﬁltered with 300 apertures and
analyzed for 2 ,7 -dichlorﬂuorescein (DCF) ﬂuorescence by
ﬂow cytometry (FCM). Approximately, 10,000 cells were
evaluated in each sample.
2.14. Measurement of Mitochondrial Membrane Potential
Using FCM. Rhodamine 123 was used to determine the
changes in mitochondrial membrane potential as described
previously [10]. Brieﬂy, U87 cells were incubated in 6 well
plates for overnight. After treating the cells with or without
100μM of jaceosidin for 24h and 48 h, cells were collected
in 10mL centrifuge tube by centrifugation at 1000rpm for
5min. Cells were then resuspended in 1mL PBS solution
containing 10μg Rhodamine 123 and incubated in the
dark for 30min. After incubation, cells were centrifuged at
1500rpm for 5min, supernatant was removed, pellet was
gently rinsed with PBS once and then resuspended in 500μL
PBS. After ﬁltration (300 apertures), the suspension was
analyzed by FCM.
2.15. Western Blot Analysis. U87 cells were treated with or
without 100μM jaceosidin for indicated time period, rinsed
twice with PBS, and lysed on ice with WIP cell lysis
reagent(BIOSS,BeijingBiosynthesisBiotechnologyCoLTD)
supplemented with 1% PMSF for 30min. The insoluble
protein lysate was removed by centrifugation at 12000rpm
for 15min at 4◦C. The protein concentrations were deter-
mined using NanoDrop 1000 (Thermo Scientiﬁc, USA)
spectrophotometer. 70μg of proteins were resolved on 12%
SDS-PAGE and transferred to PVDF membranes. After
blocking with 5% (w/v) nonfat milk and washing with Tris-
buﬀered saline-tween solution (TBST), membranes were
incubated with respective primary antibodies at 4◦Cf o r
overnight and washed three times with TBST. The blots were
then incubated with anti-rabbit or anti-mouse horseradish-
peroxidase-conjugated secondary antibodies for 1h. After
washing with TBST three times, signals were detected using
ECL plus chemiluminescence kit on X-ray ﬁlm (Millipore
Corporation, Billerica, USA).
2.16. Statistical Analysis. The results were expressed as the
mean ± SEM and statistically compared with the control
group or compared within the groups using one-way
ANOVA followed by “Tukey’s Multiple Comparison Test”
and, P<0.05 was considered statistically signiﬁcant.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Analytical HPLC chromatogram of isolated compound (jaceosidin) and its structure. This ﬁgure shows the retain time of
compound is 16.02min and the purity is 99.5% using the HPLC method we set. Analytical reversed-phase (RP) HPLC was performed
over C18 bonding chromatographic column (5μm, 2.1 × 150mm, XTerra) and gradient elution by (A) acetonitrile: (B) 0.2% Formic acid
(A: 0–25min, 10−90%; 25–30min, 90–100%) with ﬂow rate 0.2mL/min. Detection of wave length was 342nm.
3. Results
Bioactivity-guided phytochemical study on ethanol extract
of dried leaves of Artemisia argyi led to the isolation
and puriﬁcation of a ﬂavonoid called jaceosidin. Purity of
compound was assessed by analytical HPLC. Our HPLC
analysis showed only one single peak at a retention time of
16.02min (Figure 1), and purity of the peak was determined
to be 99.5%. Our results intimated that jaceosidin with
purity >99% could be obtained successfully by HSCCC
separation under the above-optimized conditions. To the
best of our knowledge, this is the ﬁrst report of the isolation
of jaceosidin from Artemisia argyi using HSCCC. The
structural elucidation of HSCCC pure fraction was carried
out by ESI-MS and NMR spectra as follows.
Jaceosidin. Yellow powder (methanol); ESI-MSm/z (%): 330
[M] +; mp: 229∼230◦C; molecular formula: C17H14O7; 1H
NMR (500MHz, DMSO-d6) δ: 3.89 (3H, s, OMe), 3.74 (3H,
s, OMe), 13.07 (1H, s, 5-OH), 7.55 (2H, m, H-5 ,6 ), 6.93
(1H, d, J = 8.9Hz, H-2 ), 6.58 (1H, s, H-8), 6.87 (1H, s,
H-3); 13C NMR (100MHz, DMSO-d6) δ: 163.5 (C-2), 102.6
(C-3), 181.9 (C-4), 152.6 (C-5), 131.5 (C-6), 158.1 (C-7),
94.4 (C-8), 152.5 (C-9), 103.7 (C-10), 121.5 (C-1 ), 110.2
(C-2 ),148.0(C-3 ),150.7(C-4 ),115.7(C-5 ),120.4(C-6 ),
59.8 (OCH3), 55.9 (OCH3).
The MS and NMR spectral data were consistent with
those reported [11]. The structure of jaceosidin is shown in
Figure 1.
3.1. Eﬀect of Jaceosidin on U87 Cell Proliferation. To detect
the growth inhibitory eﬀect of jaceosidin on U87 cells, we
performed MTT assay. Our results showed that jaceosidin
reduced the cell viability in a time- and dose-dependent
manner (Figure 2). The IC50 values were 300μMa n d
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Figure 2: Dose- and time-dependent eﬀect of Jaceosidin on
U87 cells viability. U87 cells were treated with various doses of
Jaceosidin for 24h and 48 h. Data are expressed as Mean ± SEM
of three independent experiments. Columns not sharing the same
superscript letter diﬀer signiﬁcantly (P<0.05).
100μM after 24h and 48h treatment, respectively. 100μM
concentration was selected for the following experiments.
3.2. Microscopic Study of U87 Cells. U87 cells’ morphological
changes were observed with phase contrast microscopy. Cells
weretreatedwithjaceosidinat100μMconcentrationfor24h
and 48h, respectively. Treated cells displayed drastic mor-
phological changes including a reduction in total number of
cells and an increase in ﬂoating cells in culture medium in a
time-dependent manner (Figures 3(b) and 3(c)).
We also examined the eﬀect of jaceosidin on mouse
splenocytes and U87 cells, using trypan blue and ﬂuorescentEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Microscopic analysis of U87 cells (a, b, c, d, e, f) and mouse splenocytes (g, h, i). (a) Untreated U87 cells; (b, c) U87 cells were
treated with 100μM/L jaceosidin for 24h and 48h, respectively, and morphological changes were assessed by phase contrast microscopy. (d)
Untreated U87 cells; (e, f) U87 cells were treated with 100μM/L jaceosidin for 24h and 48h, respectively. Dead cells stained red while viable
cells stained green. (g) Untreated splenocytes; (h, i) splenocytes were treated with 100μM/L jaceosidin for 24h and 48h, respectively. Dead
cells stained blue. (j) Data are expressed as Mean ± SEM of three independent experiments. Columns not sharing the same superscript letter
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probes calcein AM and PI respectively. Figure 3 shows
the staining of cells with calcein and PI. Untreated U87
cells (Figure 3(d)) took up calcein AM and deesteriﬁed
and retained the green calcein dye while cells treated with
jaceosidin (Figures 3(e) and 3(f))w e r eu n a b l et or e t a i n
the intracellular calcein or to exclude PI. Live (green) and
dead cells (red) were counted microscopically. The data
shows that the viability of U87 cells treated with 100μM
jaceosidin for 24h and 48h were signiﬁcantly lower (42.4%
and 56.7% resp.) compared with untreated control group.
However, jaceosidin exhibited less cytotoxic eﬀect on mouse
splenocytes as revealed by trypan blue dye exclusion method
(Figures 3(h) and 3(i)).
3.3. Jaceosidin Induces Mitotic Arrest in U87 Cells. Cell cycle
arrest is one of the major causes of cell growth inhibition.
In order to ﬁnd whether cell growth inhibition is from cell
cycle arrest at a speciﬁc phase of cell cycle, cell cycle proﬁle
was analyzed using PI staining and ﬂow cytometry analysis.
Our results showed that jaceosidin arrested the cell cycle
at G2/M phase in a time-dependent manner (Figure 4).
Treatment with jaceosidin at 100μM showed a statistically
signiﬁcant increase in G2/M phase from 14.6% to 27.3%,
55.5%, and 78.6% with a concomitant decrease in G0/G1
phase from 64.3% to 49.6%, 28.4%, and 7.3% after 12h,
24h, and 48h, respectively. However S phase experienced
signiﬁcant reduction only after 48h treatment compared to
control group.
3.4. Jaceosidin Induces Apoptosis in U87 Cells. To further
investigate jaceosidin-induced inhibitory eﬀect, U87 cells
were treated with jaceosidin as described in Materials and
Methods section and the percentages of cells undergoing
apoptosis/necrosis were determined by ﬂow cytometric anal-
ysis after staining with annexin V-FITC and PI. Our results
showed that jaceosidin caused a time-dependent apoptosis.
A signiﬁcant increase was observed in both early and late
apoptosis in 48h treatment group whereas 24h treatment
group showed signiﬁcant increase only in early apoptosis
as compared with control group (Figure 5). However, no
signiﬁcant apoptosis has been observed in 12h treatment
group.10 Evidence-Based Complementary and Alternative Medicine
Furthermore, there was signiﬁcant decrease in both early
and late apoptosis, when the cells were treated with 100μM
Ac-DEVD-CHO, a caspase 3 inhibitor (Figure 5(e)). The
data suggested that jaceosidin induces caspase-3-dependent
apoptosis in U87 cells.
3.5. Jaceosidin Induces ROS Production in U87 Cells. Flavon-
oids are strong antioxidant agents and increase intracellular
ROS production. So, we measured the level of ROS in treated
anduntreatedgroupsbystainingcellswithDCFH-DA,using
FCM. Our results showed that jaceosidin increased the level
of ROS from 4.91% to 11.9% and 19.1% after 24h and 48h
treatment, respectively. The level of ROS in positive control
group (Rose up) was 23.5% (Figure 6).
3.6. Eﬀect of Jaceosidin on Mitochondrial Membrane Potential.
Depolarization in mitochondrial membrane potential is a
characteristic feature of apoptosis. We determined mito-
chondrial membrane potential in treated and control groups
using FCM. Our results showed that mitochondrial mem-
brane potential in U87 cells treated with 100μM jaceosidin
was 80.3% and 69.6% after 24h and 48h, respectively. These
values were signiﬁcantly lower than those of control group
(97%) as shown in Figure 7.
3.7. Eﬀect of Jaceosidin on the Expression of Apoptosis Reg-
ulators. To investigate the mechanism of apoptosis in U87
glioma cells mediated by jaceosidin, expressions of some
major apoptosis regulatory proteins (p53, Bax, cytochrome
c, and caspase 3) were detected by Western blot. As shown in
Figure 8, the expression level of p53 and Bax was markedly
increased by jaceosidin accompanied with the release of
cytochrome c from mitochondria to cytosol and cleavage of
caspase3inatime-dependentmanner.Theseresultstogether
revealedthatjaceosidininducesapoptosisinU87gliomacells
through intrinsic pathway.
3.8.JaceosidinInducesApoptosis-IndependentCellCycleArrest
in U87 Cells. To characterize in detail the relationship
between cell cycle arrest and apoptosis mediated by jaceo-
sidin in U87 cells, we performed ﬂow cytometric analysis
of apoptosis and cell cycle arrest after 12h treatment with
jaceosidin. As shown in Figure 4(b), there was a statistically
signiﬁcant increase in G2/M phase with a concomitant
decrease in G0/G1 phase (P<0.05) of cell cycle after 12h
treatment, whereas no increase was observed in apoptosis
rate after 12h treatment (Figure 5(b))whichshowedthatcell
cycle arrest is an early event in U87 cell growth inhibition
induced by jaceosidin. These results were further conﬁrmed
by using a speciﬁc caspase 3 inhibitor, Ac-DEVD-CHO.
Flow cytometric analysis of U87 cells treated with 100μM
jaceosidin in the presence and absence of (100μM) caspase 3
inhibitor, Ac-DEVD-CHO was performed. Ac-DEVD-CHO
signiﬁcantly (P<0.05) inhibited apoptosis but did not
prevent the mitotic cell cycle arrest, indicating that cell cycle
arrestoccursindependentlyofapoptosisandisanearlyevent
in cell death mediated by jaceosidin (data not shown). These
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Figure 8: Eﬀect of jaceosidin on the expression of the apoptosis
regulators. U87 cells were treated with 100μM/L jaceosidin for 24h
and 48h, respectively. The levels of Bax, Cytochrome c, p53, and
caspase 3 were determined by Western blot analysis.
results together insinuated that jaceosidin detained the cell
cycle at G2/M phase and thereby induces apoptosis.
4. Discussion
Cell cycle control is one of the major regulatory mechanisms
of cell growth [12–15]. Many anticancer agents have been
reported to arrest the cell cycle at a speciﬁc checkpoint and
thereby induce apoptotic cell death [12, 14, 16, 17]. One of
the checkpoints, the G2/M checkpoint arrests the cell cycle
at G2 phase when DNA is damaged [18, 19]. P53 tumor
suppressor protein plays a key role in the regulation of cell
cycle and cell death. Activation of p53 may lead to growth
arrest at G1 or G2 phase of the cell cycle and apoptotic cell
death by multiple pathways [20–23]. In the present study,
we showed that jaceosidin is able to inhibit growth of U87
glioblastoma cells. However, this growth inhibition might be
resulted from apoptosis, necrosis, or cyclic block [24]. To
further investigate whether this eﬀect was from apoptotic
induction or cell cycle arrest, ﬂow cytometric analysis of
cell cycle and apoptosis was conducted. The ﬂow cytometric
analysis of cell cycle showed that jaceosidin induced cell cycle
arrest at G2/M phase accompanied by a reduction in G0/G1
phase in a time-dependent manner. The tumor suppressor
protein p53 has been reported previously to play a critical
role in G2/M arrest and G0/G1 arrest [25]. Because U87
cells express wild type p53, we examined possible changes in
the protein expression induced by jaceosidin treatment. We
found that p53 expression increased dramatically in the cells
treated with jaceosidin in a time-dependent manner.
Many cytotoxic agents arrest the cell cycle at G0/G1,
S, and G2/M phase and then induce apoptosis [11, 13,
15, 16]. So next, we performed ﬂow cytometric analysis
of apoptosis by FITC-labeled annexin-V and PI staining
to check whether jaceosidin could induce apoptosis in
U87 cells. The results demonstrated that jaceosidin induced
significant apoptosis in U87 cells after 24h and 48h treat-
ment. Previous studies have shown that jaceosidin induced
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through generation of reactive oxygen species [8]. We here
examined whether jaceosidin increases the intracellular level
of ROS in U87 cells. The data showed that jaceosidin
increased the level of ROS in U87 cells in a time-dependent
manner. However, pretreatment with NAC did not prevent
jaceosidin induced apoptosis and cell cycle arrest at G2/M
phase, indicating that ROS generation is not involved in
jaceosidin-induced apoptosis in U87 cells.
To check whether apoptosis is dependent on cell cycle
arrest, we performed ﬂow cytometric analysis of cell cycle
and apoptosis after 12h treatment with jaceosidin. The data
showed that 12 h jaceosidin treatment signiﬁcantly arrested
the cell cycle at G2/M phase, however no signiﬁcant increase
in apoptosis rate was observed. Furthermore, inhibition
of caspase 3 activation with Ac-DEVD-CHO attenuated
apoptosis but did not prevent mitotic arrest indicating that
apoptosis occurs downstream of the cell cycle arrest. To the
best of our knowledge, this is the ﬁrst report presenting that
jaceosidin induced apoptosis through cyclic block.
It has been reported that p53, a tumor suppressor
protein, triggers apoptosis by inducing mitochondrial outer
membrane permeabilization through Bax upregulation and
Bcl-2 downregulation [20, 26, 27]. To gain further insights
into the molecular mechanism underlying jaceosidin-in-
duced apoptosis, we examined expression of Bax protein
in cells of each group. The result indicated that expression
of Bax gradually increased in treatment groups in a time-
dependent manner. Involvement of mitochondrial pathway
in Bax-mediated apoptosis was further conﬁrmed by observ-
ing changes in mitochondrial transmembrane potential
(MTP) using ﬂow cytometry. A signiﬁcant reduction in
mitochondrial membrane potential has been observed in the
cells of treatment groups, suggesting the opening of mito-
chondrial permeability transition pores (PTP). Therefore,
we concluded that jaceosidin can promote the opening of
mitochondrial PTP by increasing the Bax/Bcl-2 ratio.
TheopeningofmitochondrialPTPcanleadtotherelease
of cytochrome c and other proapoptotic molecules from in-
termembranespacetocytosolwherecytochromecbinds and
activates caspase 9 which then leads to the activation of other
downstream caspases and ultimately caspase 3. Caspase 3 has
been identiﬁed as a key mediator of apoptosis of mammalian
cells [10, 28].
Wenextinvestigatedtheeﬀectofjaceosidinontherelease
of cytochrome c and activation of caspase 3 in U87 cells.
As shown in Figure 8, jaceosidin promoted the release of
cytochrome c and cleaved caspase 3 in a time-dependent
manner. These results are in line with those reported
previously [8, 9]. Furthermore, treatment of U87 cells with
caspase 3 inhibitor, Ac-DEVD-CHO, resulted in a signifi-
cant decrease in apoptosis indicating caspase 3 is involved
in apoptosis induced by jaceosidin. These results further
conﬁrmed that jaceosidin induced apoptosis in U87 cells
throughmitochondrial-caspase-3-dependentpathway.How-
ever, in the present study, the mechanism of p53 activation
by jaceosidin remains unclear. We are continuing our further
studies to investigate the mechanism of p53 activation by
jaceosidin.
In conclusion, our data demonstrated that jaceosidin
inhibited the growth of U87 glioblastoma cells and induced
apoptosis through cell cycle arrest, upregulation of p53 and
Bax, lowering MTP, release of cytochrome c, and cleavage
of caspase 3. Thus, jaceosidin could be developed into a
novel chemotherapeutic or chemopreventive agent against
glioblastoma.
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